Efficacy of bupropion alone and in combination with nicotine gum.

Author(s): Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, Baker TB

Affiliation(s): University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, WI 53711, USA. mep@ctri.medicine.wisc.edu

Publication date & source: 2007-09, Nicotine Tob Res., 9(9):947-54.

Publication type: Controlled Clinical Trial; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

In this double-blind, placebo-controlled smoking cessation treatment study, 608 participants were randomly assigned to receive active bupropion and active 4-mg gum (AA, n = 228), active bupropion and placebo gum (AP, n = 224), or placebo bupropion and placebo gum (PP, n = 156). Relative to the PP group, the AA and AP groups were each significantly more likely to be abstinent at 1 week, end of treatment, and 6 months but not at 12 months postquit. After the first week postquit there were no differences in abstinence rates between the AA and AP groups. We found no significant individual difference variables that moderated outcome beyond 1 week postquit.